Riskpilot← Back to searchSign inGet full accessAS MED-LAB
ASActiveOrg 921652690Søren Bulls vei 25, 1051 OsloDiagnostic imaging services and medical laboratory activities · NACE 8691Est. 1982462 employeeswww.furst.no
Revenue 2024
NOK 1B
+26% vs 2023
EBITDA margin
20.5%
+147% vs 2023
Equity ratio
35.1%
Financial strength
Net profit 2024
NOK 145,8M
+203% vs 2023
| Revenue | NOK 1B | +26% |
| EBITDA | NOK 207,9M | +147% |
| Net profit | NOK 145,8M | +203% |
| Total assets | NOK 285,1M | +4% |
| Equity | NOK 100M | -3% |
| Employees | 462 | — |
Legal name
AS MED-LAB
Org number
921652690
Legal form
Aksjeselskap
NACE code
8691 · Diagnostic imaging services and medical laboratory activities
Founded
4. januar 1982
Share capital
NOK 2 192 925
Employees
462 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder og et styremedlem i fellesskap, eller 3 styremedlemmer i fellesskap.
Company purpose
Etablering og opprettholdelse av et laboratorium å muliggjøre legers undersøkelse av pasienter, samt hva dertil henhører.
Address
Søren Bulls vei 25, 1051 Oslo
Phone
+4722603081
Website
www.furst.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 253 608 | 266 608 | 0 | 357 118 | 418 517 | 471 426 | 573 764 | 522 984 | 569 037 | 591 864 | 637 281 | 681 274 | 724 312 | 778 941 | 726 067 | 802 892 | 1 015 471 |
| Staff expenses | 104 862 | 110 878 | 118 181 | 139 186 | −181 278 | −188 769 | −242 717 | −241 585 | −248 094 | −259 310 | −274 090 | −300 383 | −296 495 | −318 345 | −322 814 | −350 454 | −378 063 |
| EBITDA | 11 836 | 15 522 | 118 181 | 27 165 | 45 109 | 70 455 | 86 023 | 33 494 | 48 849 | 53 953 | 75 351 | 70 152 | 81 130 | 65 269 | 40 296 | 84 149 | 207 928 |
| Depreciation & amort. | 6 377 | 7 331 | −0 | 18 018 | −18 791 | −20 753 | −23 121 | −16 619 | −15 493 | −15 913 | −15 716 | −14 068 | −14 911 | −18 780 | −21 223 | −22 729 | −24 150 |
| EBIT | 18 213 | 22 853 | 118 181 | 45 182 | 26 318 | 49 702 | 62 902 | 16 875 | 33 356 | 38 040 | 59 635 | 56 084 | 66 219 | 46 488 | 19 073 | 61 420 | 183 778 |
| Net financials | 1 621 | 666 | 0 | −818 | 137 | 72 | 920 | 397 | 201 | 269 | 421 | 527 | 356 | 53 | −430 | 270 | 3 309 |
| Profit before tax | 19 834 | 23 519 | 118 181 | 44 364 | 26 455 | 49 773 | 63 822 | 17 272 | 33 557 | 38 309 | 60 056 | 56 611 | 66 576 | 46 541 | 18 642 | 61 690 | 187 086 |
| Tax | 5 628 | 6 608 | −0 | 12 463 | 7 481 | 14 224 | 17 230 | 5 078 | 8 148 | 9 177 | 14 047 | 12 458 | 14 668 | 10 261 | 4 113 | 13 583 | 41 255 |
| Net profit | 14 206 | 16 911 | 118 181 | 31 901 | 18 974 | 35 549 | 46 592 | 12 194 | 25 409 | 29 133 | 46 009 | 44 153 | 51 907 | 36 280 | 14 529 | 48 107 | 145 831 |
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 104 264 | 86 256 | 162 237 | 178 903 | 142 770 | 154 860 | 213 581 | 170 406 | 194 383 | 223 469 | 194 427 | 188 065 | 242 050 | 199 957 | 211 966 | 274 720 | 285 119 |
| Equity | 59 350 | 40 154 | 43 498 | 75 400 | 34 374 | 49 923 | 74 915 | 76 752 | 102 161 | 131 294 | 51 306 | 80 095 | 39 032 | 75 298 | 89 824 | 103 008 | 99 977 |
| Long-term debt | −6 948 | −9 886 | 35 762 | 27 068 | −13 202 | −13 124 | −17 865 | −17 616 | −11 376 | −6 357 | −6 120 | −5 178 | −3 524 | −1 113 | −36 | 0 | 0 |
| Short-term debt | 37 966 | 33 028 | 60 251 | 58 310 | 95 194 | 91 813 | 120 801 | 76 038 | 80 846 | 85 818 | 137 001 | 102 792 | 199 494 | 123 546 | 122 106 | 171 711 | 185 142 |
| Total debt | 37 966 | 36 215 | 107 376 | 94 459 | 95 194 | 91 813 | 120 801 | 76 038 | 80 846 | 85 818 | 137 001 | 102 792 | 199 494 | 123 546 | 122 106 | 171 711 | 185 142 |
EBITDA margin
20.5%
This company
15.8%
Market median
+30% vs market
20082024
Equity ratio
35.1%
This company
38.2%
Market median
+8% vs market
20082024
Return on equity
145.9%
This company
18.4%
Market median
+693% vs market
20082024
Net profit margin
14.4%
This company
8.1%
Market median
+78% vs market
20082024
Asset turnover
3.56×
This company
1.12×
Market median
+218% vs market
20082024
Debt / equity
1.85×
This company
0.62×
Market median
-198% vs market
20082024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-01-01 – 2012-12-31
- Annual report 2011Filed via Brønnøysundsregistrene · Period 2011-01-01 – 2011-12-31
- Annual report 2010Filed via Brønnøysundsregistrene · Period 2010-01-01 – 2010-12-31
- Annual report 2009Filed via Brønnøysundsregistrene · Period 2009-01-01 – 2009-12-31
- Annual report 2008Filed via Brønnøysundsregistrene · Period 2008-01-01 – 2008-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
EB Deputy Member | Deputy Member | 2020 | — | — |
HS Chief Executive Officer | Chief Executive Officer | 2010 | — | — |
LB Deputy Member | Deputy Member | 2022 | — | — |
TK Deputy Member | Deputy Member | 2020 | — | — |
EC Deputy Member | Deputy Member | 2024 | — | — |
JS Deputy Member | Deputy Member | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Dr Furst Medisinsk Laboratorium As | Company | 100.0% | 100.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Ferd Lab Invest As
AS MED-LAB Board members of AS MED-LAB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Einar Bredo Herrfurth-Erichsen | Deputy Member | 0 companies |
| Håvard Selby Ebbestad | Chief Executive Officer | 0 companies |
| Lisbeth Berntsen | Deputy Member | 0 companies |
| Trude Katarina Nybakken Lund | Deputy Member | 0 companies |
| Eva Cecilie Sjule | Deputy Member | 0 companies |
| Joakim Sorthe | Deputy Member | 0 companies |
| Rune Tellefsen | Board of Directors | 0 companies |
| Maria Syse-Nybraaten | Board of Directors | 0 companies |
| Ying Chen | Board of Directors | 0 companies |
| Marie Skarbøvik Buchmann | Board of Directors | 0 companies |
| Bård Flattun Lilleeng | Board of Directors | 0 companies |
| Asle Helgheim | Board of Directors | 0 companies |
| Anna Margareta Lien | Board of Directors | 0 companies |
| Rikke Kathrine Tobiasson Reinemo | Chairman | 0 companies |